A Phase I-II Study to Determine the Safety, Pharmacokinetics and Potential Efficacy of Intravenous Administration of SB-743921 on Days 1 and 15 of a 28-Day Dosing Schedule in Patients With Non-Hodgkin Lymphoma and Hodgkin Lymphoma.

Trial Profile

A Phase I-II Study to Determine the Safety, Pharmacokinetics and Potential Efficacy of Intravenous Administration of SB-743921 on Days 1 and 15 of a 28-Day Dosing Schedule in Patients With Non-Hodgkin Lymphoma and Hodgkin Lymphoma.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Jul 2017

At a glance

  • Drugs SB 743921 (Primary)
  • Indications Hodgkin's disease; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Cytokinetics
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 16 Feb 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 06 Dec 2009 Results presented at ASH 2009, according to a Cytokinetics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top